Jazz Pharmaceuticals (JAZZ) Equity Income: 2016-2025
Historic Equity Income for Jazz Pharmaceuticals (JAZZ) over the last 8 years, with Sep 2025 value amounting to -$47,000.
- Jazz Pharmaceuticals' Equity Income rose 83.51% to -$47,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$890,000, marking a year-over-year increase of 57.72%. This contributed to the annual value of -$1.7 million for FY2024, which is 44.83% up from last year.
- Latest data reveals that Jazz Pharmaceuticals reported Equity Income of -$47,000 as of Q3 2025, which was up 91.33% from -$542,000 recorded in Q2 2025.
- In the past 5 years, Jazz Pharmaceuticals' Equity Income registered a high of $4.2 million during Q1 2021, and its lowest value of -$4.1 million during Q1 2022.
- Moreover, its 3-year median value for Equity Income was -$373,000 (2023), whereas its average is -$525,800.
- Per our database at Business Quant, Jazz Pharmaceuticals' Equity Income spiked by 2,188.46% in 2021 and then slumped by 4,416.67% in 2025.
- Jazz Pharmaceuticals' Equity Income (Quarterly) stood at -$3.0 million in 2021, then spiked by 74.13% to -$773,000 in 2022, then soared by 40.36% to -$461,000 in 2023, then skyrocketed by 96.53% to -$16,000 in 2024, then skyrocketed by 83.51% to -$47,000 in 2025.
- Its Equity Income stands at -$47,000 for Q3 2025, versus -$542,000 for Q2 2025 and -$16,000 for Q4 2024.